Trial Outcomes & Findings for A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris (NCT NCT00815633)

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

1 participants

Primary outcome timeframe

wks 1,2,3,4,5,6,7,8,9,10,11,12, 16,20,24

Results posted on

2018-05-11

Participant milestones
Measure	Alefacept Treatment Group (only one group) Alefacept: 15mg intramuscular injection weekly for 12 weeks
Overall Study STARTED	1
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	1

Reasons for withdrawal
Measure	Alefacept Treatment Group (only one group) Alefacept: 15mg intramuscular injection weekly for 12 weeks
Overall Study study terminated	1

A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris

Baseline characteristics by cohort
Measure	Alefacept n=1 Participants Treatment Group (only one group) Alefacept: 15mg intramuscular injection weekly for 12 weeks
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Sex: Female, Male Female	1 Participants n=5 Participants
Sex: Female, Male Male	0 Participants n=5 Participants

Timeframe: wks 1,2,3,4,5,6,7,8,9,10,11,12, 16,20,24

Population: study terminated before data collected

Outcome data not reported

Timeframe: wks 1,2,3,4,5,6,7,8,9,10,11,12, 16,20,24

Population: study terminated before data collected

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Icahn School of Medicine at Mount Sinai